Abstract Currently, no prognostic gene-expression signature (GES) established from node-positive breast cancer cohorts, able to predict evolution after systemic adjuvant chemotherapy, exists. Gene-expression profiles of 252 node-positive breast cancer patients (median follow-up: 7.7 years), mostly included in a randomized clinical trial (PACS01), receiving systemic adjuvant regimen, were determined by means of cDNA custom array. In the training cohort, we established a GES composed of 38 genes (38-GES) for the purpose of predicting metastasis-free survival. The 38-GES yielded unadjusted hazard ratio (HR) of 4.86 (95% confidence interval = 2.76-8.56). Even when adjusted with the best two clinicopathological prognostic indexes: Nottingham prognostic index (NPI) and Adjuvant!, 38-GES HRs were 3.30 (1.81-5.99) and 3.40 (1.85-6.24), respectively. Furthermore, 38-GES improved NPI and Adjuvant! classification. In particular, NPI intermediate-risk patients were divided into 2/3 close to low-risk group and 1/3 close to high-risk group (HR = 6.97 [2.51-19.36]). Similarly, Adjuvant! intermediate-risk patients were divided into 2/3 close to low-risk group and 1/3 close to high-risk group (HR = 4.34 [1. 64-11.48]). The 38-GES was validated on gene-expression datasets from three external nodepositive breast cancer subcohorts (n = 224) generated from different microarray platforms, with HR = 2.95 (1.74-5.01). Moreover, 38-GES showed prognostic performance in supplementary cohorts with different lymph-node status and endpoints (1,040 new patients). The 38-GES represents a robust tool able to type systemic adjuvant treated nodepositive patients at high risk of metastatic relapse, and is Pascal Jézéquel and Loïc Campion contributed equally to this work.
Introduction
In breast cancer, gene expression profiling permitted first to distinguish breast tumors into subclasses with clinical implications, and second to predict evolution of nodenegative breast cancer patients [1] [2] [3] [4] [5] . The initial focus on node-negative breast cancer subtyping resulted from the crucial decision of not treating low-risk patients who might have a favorable evolution without systemic adjuvant chemotherapy. Currently, three prognostic breast cancer tests resulting from gene expression studies are commercially available: Oncotype Dx Ò (Genomic Health, Redwood City, CA, USA), MammaPrint Ò (Agendia BV, Amsterdam, The Netherlands) and H/I Ò (AvariaDX, Carlsbad, CA, USA) [3, 6, 7] . All these tests are designed to be used in the management of node-negative breast cancer. Today, in breast cancer, no robust gene-expression signature (GES) based exclusively on node-positive patients treated by systemic adjuvant chemotherapy, and able to predict metastasis evolution, exists. Being able to type those node-positive patients would lead to orientate and include high-risk patients in new clinical trials testing novel targeted therapies. The goal of our study was thus to identify and validate a GES for the purpose of predicting metastatic relapse in node-positive patients treated by systemic adjuvant chemotherapy, and so, to enlarge the panel of prediction of breast cancer GESs.
Methods

Patients
The training cohort (TC) was composed of 252 women who had unilateral breast cancer, were node-positive, showed no evidence of metastasis at diagnosis, were younger than 65 years of age, and treated by adjuvant systemic chemotherapy. The majority of the studied patients (90.5%) was primarily included in a multicentric phase III clinical trial (PACS01) conducted by investigators from the French Federation of Cancer Center [8] . One hundred and twenty eight patients were also part of a previous study; in the present work, follow-up data were actualized [9] . Twenty four patients (9.5%) followed in the René Gauducheau Cancer Center were included based on the same inclusion criteria as those used for PACS01 trial. Briefly, after surgery, patients received intravenous adjuvant treatment with 5-fluorouracil 500 mg/m 2 , epirubicin 100 mg/m 2 and cyclophosphamide 500 mg/m 2 (FEC100) every 21 days for 6 cycles (PACS01-FEC arm and René Gauducheau Cancer Center), or 3 cycles (PACS01-FEC?Docetaxel arm). Patients were followed up for metastasis-free survival (MFS) . No bioclinical or MFS heterogeneity between the 3 subpopulations was found, allowing their pooling (supplementary Table 1 ). The median follow-up was 7.7 years (range 1.22-10.02). During the period, 65 patients showed evidence of distant MR and 47 died. This substudy of PACS01 trial was reviewed and approved by the ethics committee/institutional (CCPPRB) review board (number 1-97-13). All patients signed informed consent for research purpose.
External validation was based on independent breast cancer patients with the following inclusion criteria: available genomic profiles, node-positive and metastatic relapse (MR) well defined in order to use the same outcome definition as the one used in the TC. Hence, we extracted three subcohorts (validation cohorts [VCs] 1-3) from three published cohorts (Table 1, supplementary Table 2 ) [4, 10, 11] . No statistical heterogeneity was found between TC and VC1 ? VC2 ? VC3 for available data (estrogen receptor [ER] and 5-year MFS) (supplementary Table 3 ). To explore performance capacities of our gene signature (n-GES), a complementary study was conducted on breast cancer patients (exploratory cohorts [ECs] 1-6) who did not fulfill n-GES establishment inclusion criteria (nodemixed, node-negative and unspecified event [local relapse, metastatic relapse or cancer death]) ( Table 1, supplementary Table 2 ) [4, 5, [10] [11] [12] [13] .
Tumor tissue samples and RNA isolation All tumor tissue samples were surgically collected and immediately macrodissected by a pathologist, snap-frozen in liquid nitrogen and stored until RNA extraction. Total RNA was prepared by the CsCl-cushion, as described [14] . The quality and the quantity of RNA samples were evaluated by Agilent 2100 Bioanalyser RNA LabChip kit (Agilent Technologies, Palo Alto, CA, USA).
Nylon microarray technology
We used nylon microarrays manufactured in our lab, which contained 8,032 unique sequenced-verified cDNA clones, representing 5,776 distinct genes, chosen using the expressed sequence tag database from the NCBI with update Hs#196 (http://www.ncbi.nlm.nih.gov). The same microarray tools were used and described in previous works [9, 15, 16] . Microarray characteristics and data have been deposited in the NIH Gene Expression Omnibus (Series accession number: GSE11264) according to minimum information about a microarray experiment (http://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GSE11264).
Statistical analysis
Bioinformatics DNA microarrays were scanned at 25-lm resolution using a Fuji BAS 5000 image plate system (Raytest, Paris, France). The hybridization signals were quantified using ArrayGauge software v.1.3 (Fuji Ltd, Tokyo, Japan). For each membrane, the raw data were background noise subtracted (median value of negative controls ± 6 standard deviation), then normalized by global intensity of hybridization. Patient data were adjusted by the amount of polymerase chain reaction product spotted onto the membrane, log 2 -transformed and finally standardized (mean = 0; standard deviation = 1). Only genes well measured for at least 70% of patients were retained.
Establishment of the gene expression signature
Genes were selected by means of resampling and univariate Cox permutations techniques to minimize overfitting and to maximize stability of gene list for MFS prediction. We created 100 different random samples composed of the 2/3 of TC. For each of these 100 subsamples i (i = 1-100), we determined an unbiased predictor (p i ) with internal robust cross-validation (leave-one-out cross-validation method). One-hundred p i (i = 1-100) were thus determined. In order to increase stability of final gene list (n), only genes present in at least 50% of the unbiased resampled gene predictors p i were retained to build the n-GES. The n-GES score was calculated as the difference between the mean of the genes overexpressed genes in MR patients and the mean of the genes underexpressed genes in MR patients. To limit overfitting no weight was assigned to genes. Standardization of gene distributions permitted extrapolation of fully determined n-GES (including cutoff) onto other cohorts. Optimal cutoff between n-GES low-risk and high-risk groups was determined as the value with minimal Akaike Information Criterion (AIC). The n-GES was evaluated in VCs, separately and pooled. When at least one GES gene was missing in an external dataset, we calculated a reduced 38-GES and determined its optimal cutoff in TC. Moreover it was necessary to evaluate if this subscore was significantly correlated with 38-GES complete score to permit its use (Supplementary Appendix 1).
Survival analysis and endpoints
Time from surgery to MR (primary endpoint) was retained for GES establishment. Overall survival (OS), defined as time from surgery to death from any cause, was used to reinforce MFS analysis in TC. Survival curves were plotted according to Kaplan-Meier method and compared by means of log-rank test (or Wilcoxon log-rank test if number of events was small, in order to give greater weight to earlier events). For each univariate survival analysis, 10,000 permutation survival analyses were performed to ensure P values were not optimized by overfitting. Only parameters with permutation P \ 0.05 were entered into the forward Cox proportional hazards model. Proportional hazards assumption was verified for the final models by means of Schoenfeld residuals study and -ln(-ln(survival)) curves. Because time to distant metastasis was not specified for EC5 and EC6, time to the first cancer event (local relapse, MR or death) was used.
Sensitivity, specificity
Receiver operating characteristic (ROC) analysis with MR within 5 years as a defining point was computed. The area under the curve (AUC) was used as a measure of the signature global performance in the test set. Time-dependent ROC curves were calculated for n-GES and the best two clinical prognostic indexes: Nottingham prognostic index (NPI) and Adjuvant! (10-year OS score was used) [17] .
Clinicogenomic model establishment and classification
Firstly, multivariate Cox regression analysis was used to determine if n-GES added independent prognostic information to NPI and Adjuvant!. To rule out the possibility that our results were dependent on the choice of clinical indexes cutoff, we carried out a sensitivity analysis in which we varied the NPI raw score that defined low risk, as predicted by NPI, from 3.5 (in which case most patients were classified in the high-risk group) to 7 (in which case most patients were classified in the low-risk group). For Adjuvant!, the same analysis was done from 20% (in which case most patients were classified in the low-risk group) to 80% (in which case most patients were classified in the high-risk group). Secondly, we focused on patients with NPI and Adjuvant! intermediate risk: score 2 and 10-year OS probability between 60 and 80%, respectively. For those patients, the therapeutic decision could be facilitated by an appropriate refining, for example to orientate n-GES high-risk patients towards new clinical trials.
All analyses were performed with SAS 9.1 (SAS Institute Ins., Cary, NC), Stata 10.0 SE (Stata Corp., College Station, TX), R software (version 2.5.1) and BRB ArrayTools developed by Dr. R. Simon and A. Peng (Bethesda, MD; 2003) (http://linus.nci.nih.gov/BRB-ArrayTools.html). All statistical tests were two-sided and statistical significance was defined as P less than 0.05.
Results
The aim of this study was to examine whether the n-GES; (1) had prognostic value in node-positive patients treated by chemotherapy independently of known prognostic parameters such as age, Scarff-Bloom-Richardson grade, tumoral size, ER or number of positive nodes (alone or combined into NPI and Adjuvant!); (2) could improve classification of NPI and Adjuvant!, especially for intermediate-risk patients; (3) confirmed its performance in node-positive independent cohort; (4) had also prognostic value in node-negative patients.
Establishment of the gene expression signature
Thirty eight genes were kept ( Table 2) . Control of false discovery rate (FDR) among the differentially expressed genes was assessed by 10,000 permutations: permutation P was \0.008 and FDR was \18% for all genes but one (P = 0.014, FDR = 24%) [18] . Calculation of 38-GES relapse score is defined below (Panel). NPI and Adjuvant! scores are calculated as shown in Supplementary Appendix 2. Optimal cutoff determination for 38-GES, NPI and Adjuvant! is described in supplementary Table 4 ). AIC of the 3 classification schemes showed that the classification power of 38-GES (AIC = 641.44) was better than the NPI's one (AIC = 649.58), which itself was better than Adjuvant!'s one (AIC = 653.79) to explain the MFS. ROC analysis for MR within 5 years, as a defining point, showed that 38-GES global predictive performance (AUC = 0.779) was higher than NPI's one (AUC = 0.757) and Adjuvant!'s one (AUC = 0.751) with higher sensitivity (Fig. 1) . Time-dependent ROC curves confirmed that the global predictive performance of the 38-GES was better than that of NPI and Adjuvant! (data not shown).
Independent prognostic value of 38-GES
The gene signature adjusted hazard ratios for NPI and for the 10-year OS probability Adjuvant! score were 3.30 (95% CI 1.81-5.99) and 3.40 (95% CI 1.85-6.24), respectively (supplementary Table 4 ). Moreover sensitivity analysis showed that the 38-GES kept its independent prognostic value whatever the definition of NPI and Adjuvant! high-risk group was (supplementary Fig. 2 ). These results were also confirmed for OS analysis (supplementary Table 5 , supplementary Fig. 3) . So, relevance of a clinicogenomic model combining 38-GES and bioclinical parameters was shown. 
Gj Gi
Gi and Gj represent overexpressed and underexpressed geneexpression standardized values, respectively. No weight was assigned to genes in order to limit overfitting. 38-GES optimal cutoff in TC was 0.005. Table 6 ). NPI 2 patients with 5-year MFS = 90.4% could be separated in 2/3 with 5-year MFS = 96.7% close to NPI 1 and 1/3 5-year MFS = 76.7% close to NPI 3 (HR = 6.97, P \ 0.0001). Similarly, Adjuvant! 60-79% 10-year OS patients with 5-year MFS = 88.9% could be separated in 2/3 with 5-year MFS = 93.7% close to Adjuvant! C80% 10-year OS group and 1/3 5-year MFS = 76.9% close to Adjuvant!\60% 10-year OS group (HR = 4.34, P \ 0.0001). The same successful stratification was obtained for NPI and Adjuvant! high-risk patients (supplementary Table 6 , supplementary Fig. 4) .
Validation of the 38-GES on independent node-positive patients
Correlation study permitted us to apply reduced 38-GES on external datasets with missing genes. Coefficients range was 0.973-0.989 with all P \ 0.00001 (Supplementary Appendix 1). 38-GES significantly predicted metastatic evolution in pooled node-positive VC (HR = 2.95, 95% CI 1.74-5.01, P \ 0.0001) with good sensitivity (0.84) and good global predictive performance (AUC = 0.73) (Fig. 3) . ER was the (Fig. 4) .
Assessment of the 38-GES performance on nodenegative and ''node-mixed'' cohorts 38-GES significantly predicted MFS in pooled node-negative ECs (ER adjusted HR = 2.11, 95% CI 1.53-2.92, P \ 0.0001) and time to disease event (local relapse, metastasis and death) in mixed node cohorts (ER adjusted HR = 2.77, 95% CI 1.93-3.97, P \ 0.0001) (Fig. 4 and  supplementary Fig. 5 ).
Molecular biology of the markers
A large majority (86%) of the 38 genes showed a significant Cox univariate P-value in at least one external subcohort or cohort (Table 3) . Genes reaching or exceeding 50% of significance in the 10 groups are: UBE2C, TACC3, IL6ST, TUBB2C, TUBB3, PGK1, PPP1CA and SLC25A5. Results displayed in Table 3 and literature mining confirmed that the vast majority of the genes retained in our 38-GES are biologically relevant and linked to breast cancer. Several biological process were identified by using Gene Ontology database (http://www.geneontology.org/). In order of representation, these were: transcription (6 genes), transport (6 genes), ubiquitin-proteasome system (4 genes), microtubule-based process (4 genes), signal transduction (4 genes), proliferation (3 genes), cell cycle (3 genes), glycolysis (3 genes), immune response (3 genes), electron transport (3 genes), apoptosis (2 genes), angiogenesis (2 genes) and progression (2 genes).
Discussion
The strengths of our study are detailed below. Our methodology was based on rigorous internal cross-validation for establishment of a GES on a training cohort (representative of node-positive population), followed by external validation using clinically relevant patients. Furthermore, the size of our training cohort (n = 252) limited overoptimistic performance estimation due to model overfit and multiple training/test partitions maximized the stability of the obtained 38-gene list. This cohort was homogeneous, permitting identification of a GES not subject to potential confounding factors related to lymph node status or different systemic adjuvant treatment. Training and validation cohort homogeneity was verified and permitted extrapolation. Prognostic value of 38-GES was tested in pooled validation cohorts but also in each of validation subcohorts separately. As recommended for validation, predictor was fully developed from training cohort (including cutoff value), and predictive performance was verified using the same outcome definition. Our 38-GES was more powerful than the best classical prognostic references (NPI and Adjuvant!) and added independent prognostic information [19, 20] . Importantly, the prognostic performance of our 38-GES was confirmed in several independent data sets generated from different microarray platforms (Affymetrix, Agilent, academic cDNA [NCI]). Agreement study of the 38-GES gene expression significativities showed concordant results, which represents a response to skeptical view of microarray studies (Table 3) . These results confirmed on one hand the preanalytical and analytical robustness (different cohorts, biobanks and genomic protocols [RNA isolation, probe preparation and labeling, hybridization, microarray platforms]) of the vast majority of the 38 selected genes, and on the other hand their critical role in breast cancer prediction. Three main results therefore emerged from this study. First, the 38-GES represents a robust tool able to type systemic adjuvant treated node-positive patients at high risk of MR, and is especially powerful to refine NPI and Adjuvant! classifications. Hence, 38-GES high-risk patients should be orientated and included in new clinical trials testing new targeted therapies, while low-risk patients could still receive node-positive standard treatment. Second, genes, or cellular pathways, revealed by 38-GES might be used as targets for specific treatments of breast cancer. Third, after proper comparison with Mammaprint Ò and Oncotype Dx Ò , 38-GES could be used as a prognostic tools for node-negative breast cancer patients. Actually, since their initial description, prediction abilities of the two main GES in node-negative breast cancer (Mammaprint Ò [70-GES] and Oncotype Dx Ò [21-GES]) have evolved due to complementary studies. The 70-GES was developed for prognostic prediction of untreated node-negative breast cancer patients [3] . Soon after, this GES showed a prognostic value in node-positive patients who received adjuvant systemic treatment [4] . On the contrary, the Oncotype Dx assay was developed on a node-mixed cohort to predict distant relapse and validated in positive ER nodenegative breast cancer patients treated with adjuvant tamoxifen [6] . Since then, prognostic and predictive performance of this test has been refined by using different breast cancer cohorts [21] [22] [23] [24] [25] [26] [27] . In this work, we observed a comparable enlargement of the prediction spectrum of our [24, 28] . A last remark interests, once again, the wide spectrum of prediction. How is this performance possible despite breast cancer heterogeneity, revealed at the molecular level by numerous and concordant gene profiling studies? We propose that the information contained in our 38-GES relates to a common molecular background, in node-positive and node-negative patients, linked to bad outcome prediction, on the basis of all of our evaluation results, and especially to those obtained by using node-negative cohorts (e.g., Wang's cohort). Furthermore, the biological relevance of the majority of the selected genes strengthens this hypothesis. Disparity of prediction of our 38-GES could let us conclude that this GES is dominated by bad prognosisassociated genes which are also predictive of general chemotherapy sensitivity [29] . 
